Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea B Apolo

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Therapeutic Advances in Medical Oncology|August 4, 2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic reviewDaniel Castellano, Andrea B Apolo, Camillo Porta, et al.
Cancer|August 9, 2025
Top advances of the year: Bladder cancerAndrea B Apolo, Saad Atiq, Andre R Kydd, et al.
Journal for Immunotherapy of Cancer|December 20, 2018
Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case reportCecilia Monge, Hoyoung Maeng, Alessandra Brofferio, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 24, 2022
Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial CancersAndrea B Apolo, Pavlos Msaouel, Scot Niglio, et al.
Thyroid : Official Journal of the American Thyroid Association|April 15, 2014
Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcomaSahzene Yavuz, Andrea B Apolo, Shivaani Kummar, et al.
Urologic Oncology|September 17, 2024
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trialsLaura Oscar-Thompson, Carlos Riveros, Guru Sonpavde, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2022
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trialAndrea B Apolo, Thomas Powles, Bernard Escudier, et al.
Clinical Case Reports|January 31, 2020
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literatureLisa M Cordes, Nicole N Davarpanah, Lauren B Reoma, et al.
Radiology. Imaging Cancer|April 20, 2021
CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1Ahmad Shafiei, Mohammadhadi Bagheri, Faraz Farhadi, et al.
Current Opinion in Oncology|April 4, 2024
Organ preservation in muscle-invasive urothelial bladder cancerScot A Niglio, Juhi M Purswani, Peter B Schiff, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Therapeutic Advances in Medical Oncology|August 4, 2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic reviewDaniel Castellano, Andrea B Apolo, Camillo Porta, et al.
Cancer|August 9, 2025
Top advances of the year: Bladder cancerAndrea B Apolo, Saad Atiq, Andre R Kydd, et al.
Journal for Immunotherapy of Cancer|December 20, 2018
Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case reportCecilia Monge, Hoyoung Maeng, Alessandra Brofferio, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 24, 2022
Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial CancersAndrea B Apolo, Pavlos Msaouel, Scot Niglio, et al.
Thyroid : Official Journal of the American Thyroid Association|April 15, 2014
Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcomaSahzene Yavuz, Andrea B Apolo, Shivaani Kummar, et al.
Urologic Oncology|September 17, 2024
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trialsLaura Oscar-Thompson, Carlos Riveros, Guru Sonpavde, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2022
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trialAndrea B Apolo, Thomas Powles, Bernard Escudier, et al.
Clinical Case Reports|January 31, 2020
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literatureLisa M Cordes, Nicole N Davarpanah, Lauren B Reoma, et al.
Radiology. Imaging Cancer|April 20, 2021
CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1Ahmad Shafiei, Mohammadhadi Bagheri, Faraz Farhadi, et al.
Current Opinion in Oncology|April 4, 2024
Organ preservation in muscle-invasive urothelial bladder cancerScot A Niglio, Juhi M Purswani, Peter B Schiff, et al.
Pageof 12